Next Article in Journal
Sources of Embodied Creativity: Interactivity and Ideation in Contact Improvisation
Next Article in Special Issue
Oxidative Stress in Patients with Drug Resistant Partial Complex Seizure
Previous Article in Journal
Income and Self-Rated Mental Health: Diminished Returns for High Income Black Americans
Previous Article in Special Issue
Neuroimmunology Research. A Report from the Cuban Network of Neuroimmunology

Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease

International Center for Neurological Restoration, La Habana 11300, Cuba
The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu 610054, China
Center of Molecular Immunology, La Habana 11300, Cuba
National Center for the Production of Laboratory Animal Breeding, La Habana 10800, Cuba
Authors to whom correspondence should be addressed.
Behav. Sci. 2018, 8(5), 51;
Received: 17 April 2018 / Revised: 14 May 2018 / Accepted: 18 May 2018 / Published: 21 May 2018
Introduction: Treatment strategies in Parkinson’s disease (PD) can improve a patient’s quality of life but cannot stop the progression of PD. We are looking for different alternatives that modify the natural course of the disease and recent research has demonstrated the neuroprotective properties of erythropoietin. In Cuba, the Center for Molecular Immunology (CIM) is a cutting edge scientific center where the recombinant form (EPOrh) and recombinant human erythropoietin with low sialic acid (NeuroEPO) are produced. We performed two clinical trials to evaluate the safety and tolerability of these two drugs in PD patients. In this paper we want to show the positive results of the additional cognitive tests employed, as part of the comprehensive assessment. Materials and method: Two studies were conducted in PD patients from the outpatient clinic of CIREN, including n = 10 and n = 26 patients between 60 and 66 years of age, in stages 1 to 2 of the Hoehn and Yahr Scale. The first study employed recombinant human (rhEPO) and the second an intranasal formulation of neuroEPO. All patients were evaluated with a battery of neuropsychological scales composed to evaluate global cognitive functioning, executive function, and memory. Results: The general results in both studies showed a positive response to the cognitive functions in PD patients, who were undergoing pharmacological treatment with respect to the evaluation (p < 0.05) before the intervention. Conclusions: Erythropoietin has a discrete positive effect on the cognitive functions of patients with Parkinson’s disease, which could be interpreted as an effect of the neuroprotective properties of this molecules. To confirm the results another clinical trial phase III with neuroEPO is in progress, also designed to discard any influence of a placebo effect on cognition. View Full-Text
Keywords: cognitive; neuroprotection; Parkinson cognitive; neuroprotection; Parkinson
MDPI and ACS Style

Pedroso, I.; Garcia, M.; Casabona, E.; Morales, L.; Bringas, M.L.; Pérez, L.; Rodríguez, T.; Sosa, I.; Ricardo, Y.; Padrón, A.; Amaro, D. Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease. Behav. Sci. 2018, 8, 51.

AMA Style

Pedroso I, Garcia M, Casabona E, Morales L, Bringas ML, Pérez L, Rodríguez T, Sosa I, Ricardo Y, Padrón A, Amaro D. Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease. Behavioral Sciences. 2018; 8(5):51.

Chicago/Turabian Style

Pedroso, Ivonne, Marité Garcia, Enrique Casabona, Lilia Morales, Maria Luisa Bringas, Leslie Pérez, Teresita Rodríguez, Ileana Sosa, Yordanka Ricardo, Arnoldo Padrón, and Daniel Amaro. 2018. "Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease" Behavioral Sciences 8, no. 5: 51.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop